In a controlled laboratory evaluation published in AMB Express, researchers demonstrated that dual antifungal therapy combining fluconazole and amphotericin B successfully eliminated systemic infection caused by a drug-resistant strain of Candida albicans in mice, outperforming standard single-agent regimens. The study examined the comparative in vivo behavior of a fluconazole-resistant clinical isolate against a susceptible reference strain, evaluating organ fungal colonization alongside circulating interleukin-17 immune dynamics. Experimental findings revealed that while fluconazole monotherapy failed against the resistant strain—resulting in rapid fungal proliferation and universal mortality within seven days—combining fluconazole with amphotericin B cleared tissue colonization, rendering kidney cultures negative for viable colonies by day eleven. Concurrently, the investigators established that the resistant isolate exhibited enhanced pathogenicity in mice, causing significantly higher renal fungal burdens and eliciting a delayed, heightened inflammatory cytokine surge compared to the susceptible control.
Invasive candidiasis represents a severe and potentially life-threatening infection caused by various Candida species, constituting the most frequent systemic fungal disease among hospitalized patients in high-income nations. Clinical manifestations encompass candidemia as well as deep-seated candidiasis arising when fungal cells disseminate into sterile sites including the abdomen, peritoneum, or bone structures. Within healthcare facilities, Candida infections carry thirty-day mortality rates estimated between forty and fifty-five percent according to epidemiological data cited by the authors from Soriano and colleagues and the Centers for Disease Control and Prevention. Although antifungal pharmacotherapy has advanced, clinical management remains restricted by the limited repertoire of effective drug classes. Fluconazole, an orally bioavailable triazole agent, has long served as a primary cornerstone for managing candidiasis, yet its utility is increasingly challenged by the emergence of drug-resistant Candida albicans strains.
The biological mechanisms underlying fluconazole resistance in Candida albicans involve multifaceted molecular adaptations that complicate eradication. In their review of background literature, the authors noted that resistant isolates frequently harbor gain-of-function mutations in transcriptional regulatory genes, specifically MRR1 and UPC2, driving overexpression of efflux pumps such as CDR1 and MDR1 while altering ergosterol biosynthesis pathways. Although these adaptations prevent intracellular drug accumulation, previous studies suggest they may also influence pathogen fitness in non-selective environments, creating complex trade-offs between drug tolerance and virulence. Furthermore, resistant Candida strains frequently produce robust biofilms whose extracellular matrix physically impedes drug penetration while shielding fungal cells from host immune surveillance. Pathogen adaptations also involve biochemical modifications in cell wall constituents, including surface beta-glucan masking, which interferes with recognition by neutrophils and macrophages, facilitating immune evasion within infected tissues.
To counteract resistance and improve clearance kinetics, researchers have evaluated combination therapeutic regimens that pair distinct classes of antifungal agents. Combining fluconazole with echinocandins such as caspofungin—which selectively inhibits cell wall beta-1,3-glucan synthesis—or with polyenes such as amphotericin B—which disrupts fungal cell membrane integrity—presents complementary mechanisms of action. These combination strategies offer theoretical advantages including broader-spectrum activity, synergistic potency at reduced drug concentrations, reduced toxicity, and simultaneous targeting of multiple biological pathways to prevent resistance development. Beyond direct chemical inhibition, host immune defenses play a pivotal role in resolving systemic fungal disease. CD4-positive T lymphocytes recognize fungal cell wall patterns via pattern recognition receptors, triggering Th17 pathway activation and downstream interleukin-17A secretion. This cytokine orchestrates neutrophil recruitment and mucosal defenses, with previous work demonstrating that deficient interleukin-17 signaling increases host susceptibility to disseminated infection.
Despite theoretical advantages and clinical observations, experimental animal data comparing the virulence of drug-resistant versus susceptible isolates alongside concurrent host cytokine dynamics under combination therapy have remained scarce. To address this evidence gap, the research team obtained a clinical fluconazole-resistant Candida albicans isolate, designated PFCC1404-117, from a patient who developed a persistent kidney infection following abdominal surgery. The strain was characterized through culture on CHROMagar Candida media and molecular sequencing of the internal transcribed spacer region using ITS1 and ITS4 primers, with reference strain ATCC 10231 serving as the susceptible control. Standardized in vitro susceptibility testing conducted according to Clinical and Laboratory Standards Institute broth microdilution guidelines confirmed that the clinical isolate exhibited specific resistance to fluconazole while maintaining full susceptibility to itraconazole, voriconazole, caspofungin, and amphotericin B across triplicate tests in buffered RPMI 1640 medium.
To assess in vivo virulence and immune activation under controlled conditions, the investigators utilized female BALB/c mice aged six to eight weeks, weighing twenty to twenty-two grams, procured from the Pasteur Institute of Iran. Prior to experimentation, animals were acclimated for one week under maintained environmental conditions consisting of twenty to twenty-five degrees Celsius, forty to seventy percent relative humidity, and a twelve-hour light-dark photoperiod with unrestricted access to food and water. Both the resistant clinical strain and the susceptible reference strain were grown in yeast nitrogen base medium at twenty-eight degrees Celsius for four hours to reach stationary phase, washed in sterile phosphate-buffered saline, and calibrated to fifty million cells per milliliter. Systemic infection was established by injecting two-tenths of a milliliter of fungal suspension into the lateral tail vein across groups of nine mice, while an uninfected control group received sterile vehicle buffer.
Daily monitoring of infected cohorts over a seven-day period revealed measurable differences in pathogenic severity between the fungal strains. Average survival duration was longer among animals infected with the susceptible reference strain, which maintained a survival rate of 35.06 percent on day six compared to 20.83 percent among mice inoculated with the resistant isolate; however, statistical comparison using the log-rank Mantel-Cox test indicated that this difference did not achieve statistical significance (p > 0.05). In contrast, quantitative assessment of renal fungal burden demonstrated pronounced divergence in organ colonization. Analysis by two-way ANOVA followed by Sidak’s multiple comparisons test showed equivalent colony counts on day one (mean difference = 0.0100, p > 0.9999) and day three (mean difference = 0.0467, p = 0.9988). By day five, the resistant strain established significantly greater renal burden (mean difference = 0.6467, 95% confidence interval 0.0290 to 1.264, adjusted p = 0.0401), widening on day seven (mean difference = 0.7533, 95% confidence interval 0.1357 to 1.371, adjusted p = 0.0182), reaching 2.67 log10 colony-forming units per gram versus 1.92 log10 in susceptible infections.
Circulating immune responses quantified by enzyme-linked immunosorbent assay revealed distinct temporal cytokine kinetics between experimental groups. Serum interleukin-17 concentrations in mice infected with the resistant strain measured 43.66 picograms per milliliter on day one, 215.33 picograms on day three, 302.66 picograms on day five, and 259 picograms per milliliter on day seven. Animals infected with the susceptible strain exhibited corresponding values of 39.66 picograms on day one, 186 picograms on day three, 256.66 picograms on day five, and 210 picograms per milliliter on day seven. Two-way analysis of variance with Tukey’s multiple comparisons test confirmed that serum interleukin-17 concentrations did not differ significantly between cohorts on days one or three. However, the resistant strain elicited significantly higher cytokine levels on day five (mean difference = 46.00, 95% confidence interval 2.675 to 89.32, adjusted p = 0.0356) and day seven (mean difference = 49.00, 95% confidence interval 5.675 to 92.32, adjusted p = 0.0240), with both groups showing significant elevation over uninfected controls from day three onward (p < 0.0001).
To evaluate therapeutic efficacy against systemic candidiasis, the research team established six treatment arms comprising eighteen mice each, initiating daily interventions on day five post-infection across three sequential weeks. The investigation evaluated three monotherapies—fluconazole at one milligram per kilogram, caspofungin at five milligrams per kilogram, and amphotericin B at five-tenths of a milligram per kilogram—alongside two combination regimens consisting of fluconazole with caspofungin and fluconazole with amphotericin B at identical doses, with an untreated control group receiving sterile saline. Renal fungal burden was evaluated through scheduled serial sacrifices across days two through seventeen. During the initial phase, all groups maintained low baseline colonization, but by day five, untreated controls and fluconazole-treated resistant cohorts exhibited sharp fungal increases exceeding 1.0 log10 colony-forming units per gram. Fluconazole monotherapy failed against the resistant isolate, resulting in peak fungal loads on day seven and universal mortality within seven days, reflecting significant burden differences over susceptible infections at day five (mean difference = 0.8933, adjusted p < 0.0001) and day seven (mean difference = 1.820, adjusted p < 0.0001).
In contrast to the failure of single-agent fluconazole, monotherapies using caspofungin or amphotericin B and both dual-drug regimens successfully reversed infection progression, initiating continuous declines in renal colony counts by day seven. Notably, the combination of fluconazole and amphotericin B achieved the most rapid antimicrobial clearance, suppressing renal colonization to undetectable levels by day eleven. Statistical comparisons using two-way ANOVA and Tukey’s test demonstrated that in susceptible infections at day five, amphotericin B combined with fluconazole differed significantly from caspofungin combined with fluconazole (mean difference = -0.3933, 95% confidence interval -0.7486 to -0.03807, p = 0.0245). At day seven, amphotericin B plus fluconazole produced significantly lower fungal counts than caspofungin plus fluconazole (mean difference = -0.6727, p < 0.0001) and caspofungin monotherapy (mean difference = -0.5427, p = 0.0009). Among mice infected with the resistant isolate, amphotericin B plus fluconazole similarly achieved significantly lower fungal burden than caspofungin plus fluconazole at day seven (mean difference = -0.6247, 95% confidence interval -1.047 to -0.2023, p = 0.0234). Histopathological examination of kidney sections stained with haematoxylin and eosin at 400-times magnification confirmed that while untreated and fluconazole-treated tissues exhibited prominent hyphae and yeast cells at day seven, and caspofungin or amphotericin B monotherapies retained residual yeast cells at day seventeen, the fluconazole-amphotericin B combination achieved complete absence of yeast cells. The authors noted study limitations, including reliance on a murine model, testing a single resistant isolate, limited cytokine profiling, and the absence of direct correlations between immune markers and tissue fungal burden.
Subject of Research: Combination antifungal therapy and immune response against drug-resistant Candida albicans in mice
Article Title: Combination antifungal therapy against resistant C. albicans: efficacy and immune response in mice
Article References: Taghizadeh-Maleki, A., Hatami, F., Seyedjavadi, S.-S., Asghari-Paskiabi, F., & Jahanshiri, Z. (2026). Combination antifungal therapy against resistant C. albicans: efficacy and immune response in mice. AMB Express, 16(1), Article 100. https://doi.org/10.1186/s13568-026-02085-7
Image Credits: AI Generated
DOI: 10.1186/s13568-026-02085-7
Keywords: Candida albicans, Antifungal Resistance, Fluconazole, Amphotericin B, Caspofungin, Combination Therapy, Interleukin-17, Murine Model, Combination, antifungal, therapy, against
News Source: Gregory Coleman. (November 10, 2026). Fluconazole and Amphotericin B Combination Clears Resistant Candida in Mice. Scienmag.



